Time filter

Source Type

News Article | May 25, 2017
Site: www.prnewswire.com

Early this month, the International Congress and Convention Association (ICCA) puts Thailand on the 24th world's association meeting destination, up from the 27th of last year. In addition, the rank of Bangkok also jumped from the 16th to 12th in the same survey by ICCA. Mr. Chiruit Isarangkun Na Ayuthaya, Acting President of TCEB said the improved ranking reflects the high preference related to Thai competitiveness and professionalism in the world's MICE industry thus bringing in increasing number of such events to Thailand. An initial survey indicates that during the period from June to December this year, about 360 events are being organized in Thailand, about 75% of them are international scale conferences and trade exhibitions. "Thailand popularity is on the rise. We see some exceptional large events coming to Thailand such as Thaifex-World of Food Asia that is expected to draw 70,000 audiences to the show in early June. And last month, Thailand was the host of Intermatch at 31,000 audiences and Infinitus at 8,000 audiences," Mr. Chiruit said. In 2015, the Thai MICE industry generated the total direct revenue of 150 billion baht, responsible for 164,000 jobs with a GDP contribution of 0.77%. Unlike the free port destination such as Singapore and Hong Kong, Mr. Chiruit said Thailand rising popularity is a result of collaboration among private and government parties involved such as the immigration bureau, the department of customs, the Food and Drug Administration and Bangkok Metropolitan Administration, that helps raise Thailand competitiveness. Off the 360 events planned for the second half of this year, over 60% will take place in Bangkok and the rest will be in Pattaya, Phuket and Chiang Mai. More venues are being built in major provinces such as Khon Kaen and Nakhon Ratchasima. This provides opportunities for organizer and delegate new facilities as well as cultural charms. Acting President of TCEB said TCEB would strengthen the collaboration and enhance the competitiveness of other major cities to meet international standard. "A development program will be introduced for cities and provinces like Pattaya, Chiang Mai and Khon Kaen. We hope to provide more venues and more locations. It creates a win-win situation for the organizer, who will get new experience and new service, while the cities get wider exposure pluses increasing income for the local people," Mr. Chiruit. Thailand Convention & Exhibition Bureau (TCEB) - the government leading edge agency - has been the key to success for a wide range of global & regional business events since 2004. With our key strategic model, Growth Driver; TCEB works as your strategic business partner, delivers creative ideas, and provides solutions from our capable resources for every scale and various customised business events. TCEB has formed numerous collaborations and networks linked to open up grand new chapters of business opportunities, and to strategically enhance every business success with special care that will spur lasting advancement and achievements. Our goal is to equipping business events industry at national, regional, and global stage for continuous development, long-term growth and sustainable success. For further information, please contact: Corporate Communications Division To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/thai-mice-reaches-new-heights-300463877.html


News Article | May 25, 2017
Site: en.prnasia.com

- Thai MICE industry stands on firm foundation as more meetings head for Thailand during second half of the year. BANGKOK, May 25, 2017 /PRNewswire/ -- With more than 300 meetings and trade shows to be organized in Thailand during the second half of this year, the Thailand Convention and Exhibition Bureau or TCEB is confident that the Thai MICE industry stands on a firm foundation and is developing plans to create a more sustainable growth. Early this month, the International Congress and Convention Association (ICCA) puts Thailand on the 24th world's association meeting destination, up from the 27th of last year. In addition, the rank of Bangkok also jumped from the 16th to 12th in the same survey by ICCA. Mr. Chiruit Isarangkun Na Ayuthaya, Acting President of TCEB said the improved ranking reflects the high preference related to Thai competitiveness and professionalism in the world's MICE industry thus bringing in increasing number of such events to Thailand. An initial survey indicates that during the period from June to December this year, about 360 events are being organized in Thailand, about 75% of them are international scale conferences and trade exhibitions. "Thailand popularity is on the rise. We see some exceptional large events coming to Thailand such as Thaifex-World of Food Asia that is expected to draw 70,000 audiences to the show in early June. And last month, Thailand was the host of Intermatch at 31,000 audiences and Infinitus at 8,000 audiences," Mr. Chiruit said. In 2015, the Thai MICE industry generated the total direct revenue of 150 billion baht, responsible for 164,000 jobs with a GDP contribution of 0.77%. Unlike the free port destination such as Singapore and Hong Kong, Mr. Chiruit said Thailand rising popularity is a result of collaboration among private and government parties involved such as the immigration bureau, the department of customs, the Food and Drug Administration and Bangkok Metropolitan Administration, that helps raise Thailand competitiveness. Off the 360 events planned for the second half of this year, over 60% will take place in Bangkok and the rest will be in Pattaya, Phuket and Chiang Mai. More venues are being built in major provinces such as Khon Kaen and Nakhon Ratchasima. This provides opportunities for organizer and delegate new facilities as well as cultural charms. Acting President of TCEB said TCEB would strengthen the collaboration and enhance the competitiveness of other major cities to meet international standard. "A development program will be introduced for cities and provinces like Pattaya, Chiang Mai and Khon Kaen. We hope to provide more venues and more locations. It creates a win-win situation for the organizer, who will get new experience and new service, while the cities get wider exposure pluses increasing income for the local people," Mr. Chiruit. Thailand Convention & Exhibition Bureau (TCEB) - the government leading edge agency - has been the key to success for a wide range of global & regional business events since 2004. With our key strategic model, Growth Driver; TCEB works as your strategic business partner, delivers creative ideas, and provides solutions from our capable resources for every scale and various customised business events. TCEB has formed numerous collaborations and networks linked to open up grand new chapters of business opportunities, and to strategically enhance every business success with special care that will spur lasting advancement and achievements. Our goal is to equipping business events industry at national, regional, and global stage for continuous development, long-term growth and sustainable success. For further information, please contact: Corporate Communications Division To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/thai-mice-reaches-new-heights-300463877.html


Martin M.,Centers for Disease Control and Prevention | Vanichseni S.,Bangkok Tenofovir Study Group | Suntharasamai P.,Bangkok Tenofovir Study Group | Sangkum U.,Bangkok Tenofovir Study Group | And 9 more authors.
PLoS ONE | Year: 2011

Background: The Bangkok Tenofovir Study was launched in 2005 to determine if pre-exposure prophylaxis with tenofovir will reduce the risk of HIV infection among injecting drug users (IDUs). We describe recruitment, screening, enrollment, and baseline characteristics of study participants and contrast risk behavior of Tenofovir Study participants with participants in the 1999-2003 AIDSVAX B/E Vaccine Trial. Methods: The Bangkok Tenofovir Study is an ongoing, phase-3, randomized, double-blind, placebo-controlled, HIV pre-exposure prophylaxis trial of daily oral tenofovir. The Tenofovir Study and the Vaccine Trial were conducted among IDUs at 17 drug-treatment clinics in Bangkok. Tenofovir Study sample size was based on HIV incidence in the Vaccine Trial. Standardized questionnaires were used to collect demographic, risk behavior, and incarceration data. The Tenofovir Study is registered with ClinicalTrials.gov, number-NCT00119106. Results: From June 2005 through July 2010, 4094 IDUs were screened and 2413 enrolled in the Bangkok Tenofovir Study. The median age of enrolled participants was 31 years (range, 20-59), 80% were male, and 63% reported they injected drugs during the 3 months before enrollment. Among those who injected, 53% injected methamphetamine, 37% midazolam, and 35% heroin. Tenofovir Study participants were less likely to inject drugs, inject daily, or share needles (all, p<0.001) than Vaccine Trial participants. Discussion: The Bangkok Tenofovir Study has been successfully launched and is fully enrolled. Study participants are significantly less likely to report injecting drugs and sharing needles than participants in the 1999-2003 AIDSVAX B/E Vaccine Trial suggesting HIV incidence will be lower than expected. In response, the Bangkok Tenofovir Study enrollment was increased from 1600 to 2400 and the study design was changed from a defined 1-year follow-up period to an endpoint-driven design. Trial results demonstrating whether or not daily oral tenofovir reduces the risk of HIV infection among IDUs are expected in 2012.


Choopanya K.,Bangkok Tenofovir Study Group | Martin M.,Health-U | Martin M.,Centers for Disease Control and Prevention | Suntharasamai P.,Bangkok Tenofovir Study Group | And 16 more authors.
The Lancet | Year: 2013

Background Antiretroviral pre-exposure prophylaxis reduces sexual transmission of HIV. We assessed whether daily oral use of tenofovir disoproxil fumarate (tenofovir), an antiretroviral, can reduce HIV transmission in injecting drug users. Methods In this randomised, double-blind, placebo-controlled trial, we enrolled volunteers from 17 drug-treatment clinics in Bangkok, Thailand. Participants were eligible if they were aged 20-60 years, were HIV-negative, and reported injecting drugs during the previous year. We randomly assigned participants (1:1; blocks of four) to either tenofovir or placebo using a computer-generated randomisation sequence. Participants chose either daily directly observed treatment or monthly visits and could switch at monthly visits. Participants received monthly HIV testing and individualised risk-reduction and adherence counselling, blood safety assessments every 3 months, and were off ered condoms and methadone treatment. The primary effi cacy endpoint was HIV infection, analysed by modifi ed intention-to-treat analysis. This trial is registered with ClinicalTrials.gov, number NCT00119106. Findings Between June 9, 2005, and July 22, 2010, we enrolled 2413 participants, assigning 1204 to tenofovir and 1209 to placebo. Two participants had HIV at enrolment and 50 became infected during follow-up: 17 in the tenofovir group (an incidence of 0.35 per 100 person-years) and 33 in the placebo group (0.68 per 100 person-years), indicating a 48.9% reduction in HIV incidence (95% CI 9.6-72.2; p=0.01). The occurrence of serious adverse events was much the same between the two groups (p=0.35). Nausea was more common in participants in the tenofovir group than in the placebo group (p=0.002). Interpretation In this study, daily oral tenofovir reduced the risk of HIV infection in people who inject drugs. Preexposure prophylaxis with tenofovir can now be considered for use as part of an HIV prevention package for people who inject drugs. Copyright © 2013 Elsevier B.V.


Komalamisra N.,Mahidol University | Srisawat R.,Mahidol University | Phanbhuwong T.,Mahidol University | Oatwaree A.S.,Bangkok Metropolitan Administration
Southeast Asian Journal of Tropical Medicine and Public Health | Year: 2011

Mosquito larvae were collected from the houses of dengue infected patients in Bangkok, Thailand from 55 sites (36 out of the 50 districts of Metropolitan Bangkok). Aedes aegypti larvae were tested against temephos using WHO bioassay techniques. Adult mosquitoes were tested for susceptibility to permethrin, deltamethrin, cyfluthrin, malathion and DDT using WHO diagnostic doses. Most of the larvae tested were susceptible to temephos. Only few specimens were resistant to temephos. Most adult mosquitoes were highly susceptible to malathion. Deltamethrin resistance was seen in 6 districts of Bangkok. Variable levels of susceptibility were seen with cyfluthrin. Most of the specimens showed resistance to permethrin and all specimens were resistant to DDT.


Martin M.,Thailand MOPH U.S. CDC Collaboration | Martin M.,Centers for Disease Control and Prevention | Vanichseni S.,Bangkok Tenofovir Study Group | Suntharasamai P.,Bangkok Tenofovir Study Group | And 12 more authors.
PLoS ONE | Year: 2014

Introduction: HIV spread rapidly among people who inject drugs in Bangkok in the late 1980s. In recent years, changes in drug use and HIV-associated risk behaviors have been reported. We examined data from the Bangkok Tenofovir Study, an HIV pre-exposure prophylaxis trial conducted among people who inject drugs, to assess participant risk behavior and drug use, and to identify risk factors for HIV infection. Methods: The Bangkok Tenofovir Study was a randomized, double-blind, placebo-controlled trial. HIV status was assessed monthly and risk behavior every 3 months. We used generalized estimating equations logistic regression to model trends of injecting, needle sharing, drugs injected, incarceration, and sexual activity reported at follow-up visits; and proportional hazards models to evaluate demographic characteristics, sexual activities, incarceration, drug injection practices, and drugs injected during follow-up as predictors of HIV infection. Results: The proportion of participants injecting drugs, sharing needles, and reporting sex with more than one partner declined during follow-up (p<0.001). Among participants who reported injecting at enrollment, 801 (53.2%) injected methamphetamine, 559 (37.1%) midazolam, and 527 (35.0%) heroin. In multivariable analysis, young age (i.e., 20-29 years) (p = 0.02), sharing needles (p<0.001), and incarceration in prison (p = 0.002) were associated with incident HIV infection. Participants reporting sex with an opposite sex partner, live-in partner, casual partner, or men reporting sex with male partners were not at a significantly higher risk of HIV infection compared to those who did not report these behaviors. Conclusion: Reports of HIV-associated risk behavior declined significantly during the trial. Young age, needle sharing, and incarceration were independently associated with HIV infection. Sexual activity was not associated with HIV infection, suggesting that the reduction in HIV incidence among participants taking daily oral tenofovir compared to those taking placebo was due to a decrease in parenteral HIV transmission.


Martin M.,Health-U | Martin M.,Centers for Disease Control and Prevention | Vanichseni S.,Bangkok Tenofovir Study Group | Suntharasamai P.,Bangkok Tenofovir Study Group | And 14 more authors.
AIDS | Year: 2015

Objective: To describe participant adherence to daily oral tenofovir in an HIV preexposure prophylaxis (PrEP) trial, examine factors associated with adherence, and assess the impact of adherence on the risk of HIV infection. Design: The Bangkok Tenofovir Study was a randomized, double-blind, placebo-controlled trial conducted among people who inject drugs, 2005-2012. Methods: Participants chose daily visits or monthly visits. Study nurses observed participants swallow study drug and both initialed a diary. We assessed adherence using the diary. We examined adherence by age group and sex and used logistic regression to evaluate demographics and risk behaviors as predictors of adherence and Cox regression to assess the impact of adherence on the risk of HIV infection. Results: A total of 2413 people enrolled and contributed 9665 person-years of follow-up (mean 4.0 years, maximum 6.9 years). The risk of HIV infection decreased as adherence improved, from 48.9% overall to 83.5% for those with at least 97.5% adherence. In multivariable analysis, men were less adherent than women (P = 0.006) and participants 20-29 years old (P < 0.001) and 30-39 years old (P = 0.01) were less adherent than older participants. Other factors associated with poor adherence included incarceration (P = 0.02) and injecting methamphetamine (P = 0.04). Conclusion: In this HIV PrEP trial among people who inject drugs, improved adherence to daily tenofovir was associated with a lower risk of HIV infection. This is consistent with trials among MSM and HIV-discordant heterosexual couples and suggests that HIV PrEP can provide a high level of protection from HIV infection. Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.


PubMed | Bangkok Metropolitan Administration, Centers for Disease Control and Prevention, Thailand Ministry of Public Health, U.S. Center for Disease Control and Prevention and Taksin Hospital
Type: | Journal: The lancet. HIV | Year: 2016

Results of the randomised, double-blind, placebo-controlled Bangkok Tenofovir Study (BTS) showed that taking tenofovir daily as pre-exposure prophylaxis (PrEP) can reduce the risk of HIV infection by 49% in people who inject drugs. In an extension to the trial, participants were offered 1 year of open-label tenofovir. We aimed to examine the demographic characteristics, drug use, and risk behaviours associated with participants uptake of and adherence to PrEP.In this observational, open-label extension of the BTS (NCT00119106), non-pregnant, non-breastfeeding, HIV-negative BTS participants, all of whom were current or previous injecting drug users at the time of enrolment in the BTS, were offered daily oral tenofovir (300 mg) for 1 year at 17 Bangkok Metropolitan Administration drug-treatment clinics. Participant demographics, drug use, and risk behaviours were assessed at baseline and every 3 months using an audio computer-assisted self-interview. HIV testing was done monthly and serum creatinine was assessed every 3 months. We used logistic regression to examine factors associated with the decision to take daily tenofovir as PrEP, the decision to return for at least one PrEP follow-up visit, and greater than 90% adherence to PrEP.Between Aug 1, 2013, and Aug 31, 2014, 1348 (58%) of the 2306 surviving BTS participants returned to the clinics, 33 of whom were excluded because they had HIV (n=27) or grade 2-4 creatinine results (n=6). 798 (61%) of the 1315 eligible participants chose to start open-label PrEP and were followed up for a median of 335 days (IQR 0-364). 339 (42%) participants completed 12 months of follow-up; 220 (28%) did not return for any follow-up visits. Participants who were 30 years or older (odds ratio [OR] 18, 95% CI 14-22; p<00001), injected heroin (OR 15, 11-21; p=0007), or had been in prison (OR 17, 13-21; p<00001) during the randomised trial were more likely to choose PrEP than were those without these characteristics. Participants who reported injecting heroin or being in prison during the 3 months before open-label enrolment were more likely to return for at least one open-label follow-up visit than those who did not report injecting heroin (OR 30, 95 % CI 13-73; p=001) or being in prison (OR 23, 14-37; p=00007). Participants who injected midazolam or were in prison during open-label follow-up were more likely to be greater than 90% adherent than were those who did not inject midazolam (OR 22, 95% CI 12-43; p=002) or were not in prison (OR 47, 31-72; p<00001). One participant tested positive for HIV, yielding an HIV incidence of 21 (95% CI 005-117) per 1000 person-years. No serious adverse events related to tenofovir use were reported.More than 60% of returning, eligible BTS participants started PrEP, which indicates that a substantial proportion of PWID who are knowledgeable about PrEP might be interested in taking it. Participants who had injected heroin or been in prison were more likely to choose to take PrEP, suggesting that participants based their decision to take PrEP, at least in part, on their perceived risk of incident HIV infection.US Centers for Disease Control and Prevention and the Bangkok Metropolitan Administration.


PubMed | Bangkok Tenofovir Study Group, Bangkok Metropolitan Administration, Thailand Ministry of Public Health, Thailand MOPH U.S. CDC Collaboration and Centers for Disease Control and Prevention
Type: Clinical Trial | Journal: PloS one | Year: 2015

Rapid easy-to-use HIV tests offer opportunities to increase HIV testing among populations at risk of infection. We used the OraQuick Rapid HIV-1/2 antibody test (OraQuick) in the Bangkok Tenofovir Study, an HIV pre-exposure prophylaxis trial among people who inject drugs.The Bangkok Tenofovir Study was a randomized, double-blind, placebo-controlled trial. We tested participants oral fluid for HIV using OraQuick monthly and blood using a nucleic-acid amplification test (NAAT) every 3 months. We used Kaplan-Meier methods to estimate the duration from a positive HIV NAAT until the mid-point between the last non-reactive and first reactive oral fluid test and proportional hazards to examine factors associated with the time until the test was reactive.We screened 3678 people for HIV using OraQuick. Among 447 with reactive results, 436 (97.5%) were confirmed HIV-infected, 10 (2.2%) HIV-uninfected, and one (0.2%) had indeterminate results. Two participants with non-reactive OraQuick results were, in fact, HIV-infected at screening yielding 99.5% sensitivity, 99.7% specificity, a 97.8% positive predictive value, and a 99.9% negative predictive value. Participants receiving tenofovir took longer to develop a reactive OraQuick (191.8 days) than participants receiving placebo (16.8 days) (p = 0.02) and participants infected with HIV CRF01_AE developed a reactive OraQuick earlier than participants infected with other subtypes (p = 0.04).The oral fluid HIV test performed well at screening, suggesting it can be used when rapid results and non-invasive tools are preferred. However, participants receiving tenofovir took longer to develop a reactive oral fluid test result than those receiving placebo. Thus, among people using pre-exposure prophylaxis, a blood-based HIV test may be an appropriate choice.ClinicalTrials.gov NCT00119106.


News Article | March 15, 2016
Site: www.reuters.com

File photo of revelers using water guns as they participate in a water fight during Songkran Festival celebrations at Silom road in Bangkok April 13, 2015. Thailand is facing its worst water shortage in two decades, with 14 out of 76 provinces hit and large swathes of agricultural land at risk. Thailand has entered its annual dry season, which typically runs from March to May, meaning the drought is likely to get worse. The Bangkok Metropolitan Administration's solution? Be a wet blanket by cutting festival days down from four to three and imposing a curfew. "This is partly symbolic, but we hope to save water too because our lakes have become deserts," said deputy Bangkok governor Amorn Kijchawengjul. "We don't want city folk splashing water around carelessly while farmers struggle." The Songkran festival, which marks Thai New Year, is often referred to as the world's biggest water fight - a time when revelers splashing water on each other and everyone, young and old, is fair game. But this year all splashing will have to stop at 9 p.m. sharp. "We'll just shut down the party," said Amorn.

Loading Bangkok Metropolitan Administration collaborators
Loading Bangkok Metropolitan Administration collaborators